The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
None
None
Parallel
IBI112
DrugIBI112 by subcutaneous injection
placebo
Drugplacebo by subcutaneous injection
Percentage of patients achieving Psoriasis Area and severity index(PASI) 75 at week 16
PASI 75 is defined as at least a 75% reduction in PASI relative to baseline
Percentage of patients achieving an static Physician's Global Assessment (sPGA) Score of Cleared (0) or Minimal (1) at Week 16
sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.
Percentage of patients achieving PASI 50 at week 16
PASI 50 is defined as at least a 50% reduction in PASI relative to baseline
Percentage of patients achieving PASI 90 at week 16
PASI 90 is defined as at least a 90% reduction in PASI relative to baseline
Percentage of patients achieving PASI 100 at week 16
PASI 100 is defined as at least a 100% reduction in PASI relative to baseline
Percentage of patients achieving an sPGA 0 at week 16
sPGA of psoriasis is used to determine the participant's psoriasis lesions overall.
Click on the lead sponsor to view all of their trials.
